Welcome to our dedicated page for Insulet news (Ticker: PODD), a resource for investors and traders seeking the latest updates and insights on Insulet stock.
Insulet Corporation (PODD) delivers innovative diabetes management solutions through its flagship Omnipod® insulin pump system. This page aggregates official news and developments about the company's medical device innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates including quarterly earnings reports, product launch announcements, regulatory milestones, and partnership agreements. All content is sourced directly from verified corporate communications to ensure accuracy.
Key coverage areas include FDA clearances for new devices, clinical study results, international market entries, and technology partnerships enhancing insulin delivery systems. The resource is particularly valuable for tracking advancements in tubeless pump technology and automated insulin dosing integrations.
Bookmark this page for streamlined access to Insulet's latest developments in diabetes care innovation. Check regularly for updates that may impact long-term growth strategies or patient care standards.
Insulet Corporation (NASDAQ: PODD) reported its financial results for the year ended December 31, 2022, achieving full year revenue of $1.3 billion, up 18.8% from 2021. Total Omnipod revenue reached $1.2 billion, marking a 23.4% increase. However, Drug Delivery revenue declined by 34.2%. The company's gross margin fell to 61.7%, and operating income dropped significantly to $37.6 million from $126 million year-over-year. Adjusted net income was $91.1 million, compared to $59.2 million in the previous year. For 2023, Insulet anticipates revenue growth of 14% to 19% and plans a launch of the Omnipod 5.
Insulet Corporation (NASDAQ: PODD) presented new real-world evidence for its Omnipod 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) from February 22-25, 2023, in Berlin. The data showcased the device's effectiveness across various demographics, demonstrating strong glycemic control with minimal low glucose incidents. Omnipod 5, which has been available in the U.S. since August 2022, is set to launch in the UK mid-year and Germany later this year. Insulet plans to discuss future clinical trials and innovations at the symposium.
Insulet Corporation (NASDAQ: PODD) has acquired the assets of Automated Glucose Control LLC (AGC) for $25 million. The acquisition includes vital licenses and intellectual property linked to automated insulin delivery technology, developed in partnership since 2016. Insulet's Executive Vice President, Eric Benjamin, highlighted the long-standing collaboration that led to advancements in managing diabetes. This strategic move aims to enhance the Omnipod 5 Automated Insulin Delivery System and strengthen Insulet's position in diabetes management.
Insulet Corporation (NASDAQ: PODD) will present at two major investor conferences: the Raymond James 44th Annual Institutional Investors Conference on March 7, 2023, in Orlando, FL, at 9:15 a.m. ET, and the Cowen 43rd Annual Health Care Conference on March 8, 2023, in Boston, MA, at 10:30 a.m. ET. Interested investors can listen to live audio webcasts at investors.insulet.com/events. The company is a leader in tubeless insulin pump technology with its Omnipod brand, offering innovative products like the Omnipod 5 Automated Insulin Delivery System, simplifying insulin delivery for diabetes management.
Insulet Corporation (NASDAQ: PODD) has acquired key assets related to Bigfoot Biomedical's automated insulin delivery technologies for $25 million. This acquisition strengthens Insulet's intellectual property (IP) portfolio by nearly doubling its existing patents, vital for future innovations in diabetes management. Bigfoot will utilize the funds to expand its Bigfoot Unity® Diabetes Management System. The collaboration aims to enhance the delivery of insulin through both pump-based and connected injection support technologies, addressing diverse patient needs. This move underscores Insulet's commitment to investing in innovative diabetes care solutions.
Insulet Corporation (NASDAQ: PODD) has announced its plans to release financial results for the fourth quarter and full year of 2022 on February 23, 2023, following market closure. The management will conduct a conference call at 4:30 p.m. ET on the same day, with access via the Company's Investor Relations website. Insulet is recognized for its Omnipod product platform, which offers innovative solutions for diabetes management, including the Omnipod® 5 Automated Insulin Delivery System. This groundbreaking system integrates with continuous glucose monitoring, bringing advanced insulin delivery to users.
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, will present at two key investor conferences in December 2022 and January 2023. The first event is the Nasdaq 47th Investor Conference in London on December 6, 2022, at 6:30 a.m. ET, followed by the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on January 10, 2023, at 1:30 p.m. ET. Live audio webcasts of the presentations can be accessed through Insulet's investor relations website.
Insulet aims to simplify diabetes management with its innovative Omnipod product platform.
Insulet Corporation (NASDAQ: PODD) announced a medical device correction for its Omnipod® 5 Automated Insulin Delivery System due to issues with the charging port and cable, which have melted or deformed in some cases. The company received 24 reports but noted that no serious injuries have occurred. This correction is voluntary and informed by the FDA. Users are advised to check for issues and are being contacted with instructions. Insulet provides customer support via a dedicated hotline and offers further information on its website.
Insulet Corporation (NASDAQ: PODD) has voluntarily initiated a Medical Device Correction for the Omnipod DASH® Personal Diabetes Managers due to reported battery issues, including swelling, leakage, and overheating risks. The FDA and regulatory agencies were informed. There are 50 complaints, but no serious injuries or deaths have occurred. An update to the device is anticipated in the coming months to address these issues, with direct communications sent to affected users. Safety remains a top priority, and customer support is available 24/7 for concerns.
Insulet Corporation (NASDAQ: PODD) reported third-quarter 2022 revenue of $340.8 million, a 23.7% increase year-over-year. The total Omnipod revenue reached $326.1 million, up 25.3%. U.S. sales surged by 42.4% to $238.1 million, while international revenue dipped by 5.5%. Despite this growth, the gross margin fell to 55.3% due to a $36.8 million charge for a device correction. The company posted a net loss of $5.2 million compared to a profit of $12.6 million last year. Insulet raised its revenue growth guidance for 2022, projecting an 18% to 19% increase.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
